Cerus Corporation (NASDAQ:CERS) — Market Cap & Net Worth
Market Cap & Net Worth: Cerus Corporation (CERS)
Cerus Corporation (NASDAQ:CERS) has a market capitalization of $494.91 Million ($494.91 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12491 globally and #3043 in its home market, demonstrating a -5.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cerus Corporation's stock price $2.47 by its total outstanding shares 200368974 (200.37 Million). Review CERS total liabilities to assess the company's total debt and financial obligations.
Cerus Corporation Market Cap History: 2015 to 2026
Cerus Corporation's market capitalization history from 2015 to 2026. Data shows change from $1.27 Billion to $494.91 Million (-5.62% CAGR).
Index Memberships
Cerus Corporation is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.02% | #330 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #1212 of 3165 |
Weight: Cerus Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cerus Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cerus Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.00x
Cerus Corporation's market cap is 2.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $871.61 Million | $37.18 Million | -$62.91 Million | 23.44x | N/A |
| 2017 | $677.25 Million | $43.57 Million | -$60.59 Million | 15.54x | N/A |
| 2018 | $1.02 Billion | $60.91 Million | -$57.56 Million | 16.68x | N/A |
| 2019 | $845.56 Million | $74.65 Million | -$71.24 Million | 11.33x | N/A |
| 2020 | $1.39 Billion | $91.92 Million | -$59.86 Million | 15.08x | N/A |
| 2021 | $1.36 Billion | $130.86 Million | -$54.38 Million | 10.43x | N/A |
| 2022 | $731.35 Million | $162.05 Million | -$42.83 Million | 4.51x | N/A |
| 2023 | $432.80 Million | $156.37 Million | -$37.49 Million | 2.77x | N/A |
| 2024 | $308.57 Million | $180.27 Million | -$20.92 Million | 1.71x | N/A |
| 2025 | $412.76 Million | $206.13 Million | -$15.63 Million | 2.00x | N/A |
Competitor Companies of CERS by Market Capitalization
Companies near Cerus Corporation in the global market cap rankings as of June 17, 2026.
Key companies related to Cerus Corporation by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #149 globally with a market cap of $157.58 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #205 globally with a market cap of $118.86 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #236 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #244 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #149 | Abbott Laboratories | NYSE:ABT | $157.58 Billion | $90.62 |
| #205 | Stryker Corporation | NYSE:SYK | $118.86 Billion | $310.58 |
| #236 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #244 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $81.32 |
Cerus Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, Cerus Corporation's market cap moved from $1.27 Billion to $ 494.91 Million, with a yearly change of -5.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $494.91 Million | +19.90% |
| 2025 | $412.76 Million | +33.77% |
| 2024 | $308.57 Million | -28.70% |
| 2023 | $432.80 Million | -40.82% |
| 2022 | $731.35 Million | -46.40% |
| 2021 | $1.36 Billion | -1.59% |
| 2020 | $1.39 Billion | +63.98% |
| 2019 | $845.56 Million | -16.77% |
| 2018 | $1.02 Billion | +50.00% |
| 2017 | $677.25 Million | -22.30% |
| 2016 | $871.61 Million | -31.17% |
| 2015 | $1.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Cerus Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $494.91 Million USD |
| MoneyControl | $494.91 Million USD |
| MarketWatch | $494.91 Million USD |
| marketcap.company | $494.91 Million USD |
| Reuters | $494.91 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offer… Read more